Suppr超能文献

骨髓移植后长期存活患者CD8淋巴细胞的功能分析

Functional analysis of CD8 lymphocytes in long-term surviving patients after bone marrow transplantation.

作者信息

Divine M, Lecouedic J P, Gourdin M F, Oudhriri N, Zohair M, Henni T, Beaujan F, Vernant J P, Reyes F, Farcet J P

机构信息

INSERM U.91, Hôpital Henri Mondor, Créteil, France.

出版信息

J Clin Immunol. 1988 Mar;8(2):140-7. doi: 10.1007/BF00917902.

Abstract

The recovery of T-cell populations after bone marrow transplantation (BMT) is characterized by a persistent expansion of CD8 lymphocytes. Previously, we have shown that beyond 1 year posttransplantation the CD8 lymphocytes consist, to a large extent, of CD8+ HNK1+ cells that suppress, like normal CD8 lymphocytes, immunoglobulin production in vitro. We have further investigated the functional capabilities of CD8 lymphocytes, mostly HNK1+ (from 50 to 77%), in seven long-term BMT patients. As normal, patient CD8 lymphocytes do not suppress (1) phytohemagglutinin (PHA)-induced interleukin 2 (IL2) receptor expression and IL2 responsiveness by normal T cells or (2) the mixed lymphocyte reaction of donor cells. Also as normal, patient CD8 lymphocytes can be activated into potent cytotoxic effectors. Therefore, under the present experimental conditions, the increase in the absolute number of CD8 lymphocytes in the long-term BMT patients is characterized by an expansion of the CD8+ HNK1+-cell subpopulation and a normal suppressor/cytotoxic potential on a per-CD8+ cell basis.

摘要

骨髓移植(BMT)后T细胞群体的恢复以CD8淋巴细胞的持续扩增为特征。此前,我们已经表明,移植后1年以上,CD8淋巴细胞在很大程度上由CD8 + HNK1 +细胞组成,这些细胞与正常CD8淋巴细胞一样,在体外抑制免疫球蛋白的产生。我们进一步研究了7例长期BMT患者中CD8淋巴细胞(主要是HNK1 +,占50%至77%)的功能能力。与正常情况一样,患者的CD8淋巴细胞不会抑制(1)植物血凝素(PHA)诱导的正常T细胞白细胞介素2(IL2)受体表达和IL2反应性,或(2)供体细胞的混合淋巴细胞反应。同样与正常情况一样,患者的CD8淋巴细胞可以被激活成为有效的细胞毒性效应细胞。因此,在目前的实验条件下,长期BMT患者中CD8淋巴细胞绝对数量的增加表现为CD8 + HNK1 +细胞亚群的扩增以及每个CD8 +细胞的抑制/细胞毒性潜能正常。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验